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Introduction 
 
Heptahelical G protein-coupled receptors (GPCR) are integral 
membrane proteins involved in a wide array of cell signaling pathways. 
The cannabinoid receptor CB2 that belongs to the rhodopsin-like 
(class A) GPCR is an attractive target for the development of drugs 
for management of pain, inflammation and immunological disorders 
[1-3]. Structural studies will provide critical insights into the 
molecular mechanisms of ligand binding and signal transduction, and 
can contribute to the rational design of novel specific drugs targeting 
this receptor. 
The progress in structural studies of GPCR has been relatively 
slow until recently, primarily due to (i) difficulties in obtaining large 
quantities of sufficiently pure, homogenous and functional receptors, 
(ii) conformational flexibility of GPCR that hinder their stabilization 
in detergent micelles, and (iii) high hydrophobicity of these integral 
membrane proteins that complicates preparation of well-diffracting 
crystals for X-ray crystallography. In spite of these obstacles, 
significant improvements in expression techniques, methods of 
stabilization and crystal preparation resulted in several high resolution 
structures of GPCR solved during the past few years [4-12]. 
With the notable exception of rhodopsin, most GPCR are present 
in native tissues at relatively low levels, and recombinant expression in 
a heterologous host is currently the only practical way to obtain these 
proteins in milligram quantities necessary for structural studies. The 
commonly used expression systems for GPCR include baculovirus-
infected insect cells, yeast, bacterial or mammalian cells as well as cell-
free systems [6]. Expression in insect cells has been particularly useful 
for production of receptors in milligram quantities for crystallization 
trials  [5, 9, 10, 13, 14].   However,   the   adaptation  of   insect-  or  
 
 
 
 
 
 
 
 
mammalian cells for preparation of stable-isotope labeled proteins for 
nuclear magnetic resonance (NMR) spectroscopy studies currently is 
prohibitively expensive due to the complexity of the medium and high 
cost of labeled nutrients [15]. While the expression in yeast cells has 
also been used for production of several GPCR [16, 17], this host 
may not be suitable for some receptors (including CB2) because it is 
often prone to non-homogenous glycosylation or partial proteolysis 
of target proteins [18-20].  
These considerations stimulated the development of methods of 
production of the recombinant CB2 in E. coli cells. In a series of 
publications we reported efficient expression of CB2 receptor in 
bacterial cell membranes in a fully functional form, although in the 
absence of posttranslational modifications [21], and its purification to 
over 90% homogeneity by tandem affinity chromatography [22]. 
Furthermore, the protein can be labeled with stable isotopes by 
fermentation of E. coli in a defined-composition medium 
supplemented with labeled nutrients [23]. This robust methodology 
for expression and labeling of CB2 opens up exciting opportunities to 
study this receptor by NMR spectroscopy. 
In addition to the availability of milligram quantities of purified 
receptor, structural methods require sufficient stability of the protein 
over extended periods of time. While solubilization in detergents is 
needed for isolation of GPCR from cell membranes, preventing 
irreversible denaturation of these proteins in detergent micelles is a 
notoriously difficult task [6-8, 13, 24-26]. Here we review the 
methodological approaches for stabilization and reconstitution of the 
purified receptor in lipid bilayers and preparation of milligram 
quantities of functional CB2 suitable for studies by a broad array of 
biophysical techniques. 
 
Experimental design 
 
Several laboratories reported expression of either full-length or 
truncated human cannabinoid receptors in a heterologous host 
including bacteria, yeast, baculovirus-infected insect cells and cell-free 
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system [18-20, 27-32]. While production of a ligand binding-
competent receptor was demonstrated, no successful attempt was 
reported to produce and purify the expressed receptor in large 
quantities, to label it with stable isotopes and to stabilize it in a 
functional form suitable for biophysical studies.  
A comprehensive program initiated in our laboratory has an 
objective to develop an extensive set of methods for recombinant 
expression of human cannabinoid receptor CB2 in large quantities in 
E. coli, efficient purification, stabilization in detergent micelles, and 
functional characterization. Various elements of this methodology 
were reported in several earlier publications [21-24, 33, 34], and the 
general outline of the experimental strategy is given in Figure 1. The 
initial stage of the study focused on establishing conditions for 
production of the functional CB2 receptor in E. coli cells cultivated in 
a rich 2xYT medium while subsequent work dealt with the adaptation 
of expression protocols to preparation of stable-isotope labeled 
receptor by fermentation in minimal salt media of defined 
composition. Particular attention was devoted to maximizing the 
recombinant protein yield, reducing the cost of fermentation, 
stabilization of the functional CB2 receptor in detergent micelles and 
achieving high purity and homogeneity of protein preparations. In 
parallel, methods for functional analysis of the purified receptor by 
ligand binding and G protein activation (either in detergent micelles 
or reconstituted in lipid bilayers) were developed. Furthermore, the 
purified CB2 was characterized by several biophysical techniques 
including NMR spectroscopy, surface plasmon resonance, CD-, IR- 
and fluorescent spectroscopy, and differential scanning calorimetry. 
 
 
 
 
 
 
Expression of CB2 receptor in E. coli 
 
The choice of the bacterial host, copy number of the expression 
vector, strength of the promoter, composition of the culture media, 
concentration of the inducer as well as temperature, method and 
duration of induction play critical roles in determining both the total 
yield of the fusion protein and the recovery of functional receptor. 
Several E. coli strains including BL21 (DE3), DH5a, KRX, 
RosettaGami, C41 and C43 were compared for their effectiveness in 
production of fusion CB2, and BL21 (DE3) was selected based on 
higher yield of the recombinant protein and high levels of functional 
activity of the receptor [21, 22, 35].  
Limited availability of tRNAs for rarely used codons may play a 
role in controlling the rate of translation of the recombinant 
polypeptide [36, 37]. We optimized the codon usage of the human 
CB2 gene for bacterial expression by designing a synthetic gene 
enriched with synonymous codons reported to be frequently used in 
E. coli [38]. However, the use of the synthetic gene did not increase 
the yield of CB2 when introduced into the expression vector under the 
control of the lac promoter; it even resulted in slightly lower levels of 
the recombinant receptor compared to the original mammalian gene 
sequence (Yeliseev et al, unpublished). This suggests that the rate of 
folding and insertion of CB2 in the bacterial membrane rather than the 
rate of translation has a critical influence over the yield and correct 
fold of the recombinant receptor. Therefore, in all subsequent 
experiments the native sequence of the human CB2 gene was used. 
The nature and relative position of expression partners fused to 
the target protein can change dramatically the expression level and 
activity of the recombinant GPCR [6]. Therefore, a variety of plasmid 
constructs containing different combinations of several expression- 
and solubility tags were tested for their efficiency in production of 
functional CB2. Figure 2 depicts selected expression constructs 
currently utilized in our laboratory.  
 
 
 
 
 
 
To avoid misfolding and aggregation of the recombinant CB2, and 
to ensure its expression in a functional form in E. coli, an appropriate 
N-terminal fusion partner is required [22]. For example, the N-
terminal Haloalkane dehalogenase (Halotag) significantly increased 
the levels of the fusion CB2 protein but a large fraction of the receptor 
was not functional (likely due to misfolding and aggregation) [35]. 
On the other hand, the use of the maltose-binding protein of E. coli 
(MBP) fused at the N-terminus of CB2 was highly beneficial for the 
high-level functional expression of this receptor [21, 22, 28]. The 
MBP is normally localized in the periplasm of E. coli, and the 
transport of the nascent polypeptide across the cytoplasmic membrane 
is facilitated by the Sec translocon system that recognizes the leader 
sequence of MBP [40]. Importantly, the full length sequence of MBP 
is required for the maximal beneficial effect. Expression of CB2 fused 
to only the 26 amino acid-long leader sequence resulted in a 
significantly lower (~50-100-fold) expression and activity suggesting 
that the whole-length MBP is highly beneficial to ensure the correct 
fold of CB2 in E. coli membranes [22]. A recent study reported the 
use of N-terminal Mistic (from Bacillus subtilis) and C-terminal 
TarCF (fragment of bacterial aspartate chemosensory transducer) for 
functional expression of CB2 in E. coli [31]. However, the density of 
ligand-binding sites in cell membranes was an order of magnitude 
lower than that of MBP-containing expression constructs [21]. 
Figure 1. Experimental strategy for preparation of functional CB2 (adapted 
from [24]). 
 
Figure 2. Schematic representation of constructs for expression of CB2 
fusion protein in E. coli (adapted from [22, 33, 39]). 
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The topology of the receptor in cytoplasmic membranes was 
determined by measuring the in vivo biotinylation of the fusion 
protein containing a biotin-recognition sequence placed in various 
positions relative to CB2 [33]. When expressed as a fusion with MBP, 
the N-terminus of CB2 is exposed to the periplasmic space while its 
C-terminal part is localized to the cytoplasm of E. coli. The 
predominant in vivo biotinylation of the C-terminal biotin-
recognition sequence suggests that MBP promotes the insertion of the 
fusion protein into cytoplasmic membranes in an N-terminus-out 
orientation. Furthermore, one can speculate that the oxidative redox 
environment of the periplasm facilitates the formation of the 
proposed disulfide bond between the cysteine residues 174 and 179 
in extracellular loop 2 [33] which may have an important role in 
stabilizing the functional fold of CB2 [41]. The expression of CB2 can 
be further increased by 30-40% by fusing the E. coli thioredoxin 
(Trx) to the C-terminus of CB2 [22]. Both MBP and Trx expression 
partners can be selectively removed if desired by cleaving the fusion 
with the specific TEV protease at recognition sequences flanking the 
receptor. 
 
 
 
 
 
 
 
 
 
For purification by tandem affinity chromatography, two small 
affinity tags were added at the opposing ends of the recombinant CB2 
receptor [22, 33, 39].  Examples of several such constructs are shown 
in Figure 2. The affinity tags either can be removed in the course of 
purification or left fused to the purified receptor, depending on the 
requirements of downstream applications. Examples of the efficient 
purification of CB2 include sequential Ni-NTA and StrepTactin 
affinity chromatography (for His- and Strep-tag pair) [22], His-tag/ 
Bio-tag [33] and Rho-tag/ His-tag pairs [39]. 
Proper alignment of the rates of protein synthesis with the 
capacity of cells for correct folding and membrane insertion of the 
nascent polypeptide is essential for production of the functional 
receptor [23]. Excessively high rates of protein synthesis typically lead 
to misfolding of membrane proteins and formation of inclusion 
bodies. Therefore, the expression of CB2 is performed from the low 
copy number vector based on the pMal-p2 backbone from the weak 
lac promoter as described earlier [21].  
Likewise, lowering the cultivation temperature from 37 oC to 20 
oC has a clear beneficial effect for the functional expression of CB2 
(Figure 3) [23]. However, further lowering the temperature to 16 oC 
has negative consequences because the accumulation of the target 
protein decreases substantially. On the other hand, the cultivation at 
higher than 20 oC temperature (27oC or 30oC) resulted in a 2-3.5 
fold increase in the levels of the fusion CB2 in membranes but a large 
fraction of the accumulated receptor was not functional [23]. 
Therefore, an induction temperature of 20 oC was deemed optimal for 
shake-flask experiments. 
The typical expression protocol for production of recombinant 
CB2 includes cultivation of E. coli BL21 cells harboring an expression 
plasmid, in shake-flask, in a double-strength YT medium 
supplemented with 0.5-1% glucose to adequately support cell growth. 
Cells are grown in 2L baffled flasks containing 500 mL of medium 
and antibiotic, at 230 rpm to maintain adequate aeration level, and 
the target protein production is induced by addition of 0.5 mM 
IPTG, at 20oC. The cultivation then continues for another 40 hours, 
and the expression levels of CB2 can reach 0.5 mg/ L of culture or 
higher, depending on a construct used [21, 22]. 
For stable-isotope labeling of CB2 the expression in a minimal salt 
medium (MSM) in a fermentor was developed. E. coli cells harboring 
the expression construct have to undergo at least three rounds of 
adaptation to the MSM that results in the cell doubling time of less 
than 2 hours. The cultivation is performed under controlled pH, 
temperature and aeration [23]. Either glucose and ammonium salts or 
a mixture of amino acids can be used as sources of carbon and 
nitrogen. The rates of accumulation of the recombinant receptor in 
cells cultivated in a fermentor are usually higher than in shake flasks, 
and the biomass at the OD600 = 20-30 or higher can be collected as 
early as 4-10 hours post-induction, depending on conditions of 
fermentation and the expression construct.  
 
Purification of recombinant CB2 
 
Purification of CB2 and removal of expression partners is typically 
performed following solubilization of the fusion protein in detergent 
micelles. By screening solubilization conditions with ~ 40 different 
detergents and combination of detergents, a mixture of the nonionic 
dodecyl maltoside (DDM) and zwitterionic CHAPS was identified as 
the most suitable for efficient extraction of the CB2 from membranes 
[21, 24]. This detergent mixture is further supplemented with a 
derivative of cholesterol, cholesteryl hemisuccinate (CHS) and a high 
affinity ligand (agonist CP-55,940 or inverse agonist SR-144,528) to 
stabilize the receptor [24]. Use of DDM, CHAPS and CHS for 
solubilization and purification was also described for neurotensin 
receptors and other GPCR [26, 42]. A possible mechanism of 
stabilization by CHS of the recombinant adenosine A2A receptor in 
DDM micelles has been proposed [43]. 
The relatively high concentration of the non-ionic detergent 
DDM (1% w/v) and zwitterionic CHAPS (0.5% w/v) is needed for 
efficient solubilization of CB2 from bacterial membranes [24]. 
However, the subsequent chromatographic purification can be 
performed at a lower concentration of DDM (0.1%), which in 
combination with 0.5% CHAPS and 0.1% CHS [21], is sufficient to 
maintain the CB2 receptor in a correctly folded, soluble form [21]. 
Since the fusion CB2 is accumulated in E. coli membranes at moderate 
levels (~0.1% of total cellular protein), a very efficient and selective 
chromatographic procedure is required to achieve the yield and purity 
of the target protein required for high resolution structural methods. 
Such commonly used chromatographic techniques as ion-exchange, 
size-exclusion or hydrophobic chromatography were not efficient, 
likely because large detergent micelles prevented proper interaction of 
the receptor with the resin (Yeliseev et al, unpublished). Efficient 
purification and recovery of CB2 was achieved by tandem affinity 
Figure 3. Expression levels and activity of CB2 in E. coli membranes as a 
function of incubation temperature. The levels of CB2 in membranes were 
quantified by Western blot, and activity – by a G protein-activation assay. 
Relative expression levels and activity of the receptor induced at 20 oC 
were set at 1 (adapted from Ref. [23]). 
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chromatography taking advantage of small affinity tags placed at 
opposing ends of the receptor (Figure 2). This approach relies on a 
tight binding of the affinity tags to their respective resins, allows fast 
removal of impurities and products of truncation of CB2, and results 
in highly pure, full-length receptor [35, 39]. 
A typical purification protocol for fusion constructs CB2-125 and 
CB2-130 (both containing C-terminal decahistidine tags) [22] begins 
with the IMAC chromatography. The binding of a shorter histidine 
tag (i.e. hexahistidine) to the Ni-NTA resin in the presence of 
detergent micelles was shown to be rather weak [21, 42]. The longer, 
decahistidine tag makes the Ni-NTA purification step much more 
efficient and typically results in a recovery of ~80% or more of the 
fusion CB2, with ~70% or higher purity [22].  The protein is eluted 
from the Ni-NTA resin in a small volume (several milliliters), and the 
expression partners can be removed from the fusion by enzymatic 
cleavage with purified recombinant TEV protease [22, 44]. The 
fusion protein sample needs to be dialyzed prior to cleavage, in order 
to lower the content of salts, imidazole (used for elution of CB2 from 
the Ni-NTA resin) and glycerol, that inhibit proteolysis [22]. For 
more efficient cleavage, the NaCl concentration should be lowered to 
100 mM or less and glycerol – to 15% or less. The reaction is 
performed for at least 4 hours or overnight at 4 oC [22]. While the 
reaction rate is much higher at higher temperatures, an increase in 
temperature above 4 oC is not recommended because it promotes 
irreversible denaturation of CB2 [24]. 
The CB2 released from the fusion is then re-captured via the 
remaining affinity tag (the N-terminal StrepTag in the case of CB2-
125 or CB2-130), and separated from TEV protease, cleavage 
products and other impurities. Similar to the Ni-NTA 
chromatography step, capture of CB2 on a StrepTactin Macroprep 
resin is performed in the presence of DDM, CHAPS and CHS. Since 
the affinity of a single Strep-tag II (WSHPQFEK ) to the resin in the 
presence of micelles is rather weak, a double repeat of this tag is 
attached to the N-terminus of CB2 to ensure a more efficient capture 
[22]. This double tag typically improves the recovery of the receptor 
to greater than 70-75%, and the purity – to greater than 90% [22]. 
An overall yield of the purified receptor can be as high as 0.3-0.5 mg/ 
L of the shake flask culture, depending on a particular construct and 
culture conditions. 
The purification of CB2 using either His-tag/ Bio-tag or His-
tag/Rho-tag pairs was described [33, 39]. The Bio-tag and Rho-tag 
have higher affinity than the His-tag to their respective resins which 
makes capture of the fusion CB2 protein from dilute solutions more 
efficient. 
 
Stabilization of CB2 
 
Recombinant CB2, like many other GPCR, is highly unstable once 
solubilized from lipid membranes in detergent micelles. The use of 
the “mild” nonionic detergent DDM and zwitterionic CHAPS was 
not only efficient for solubilization but also beneficial for maintaining 
the functional fold of CB2 in micelles for a relatively short period of 
time [24]. However, structural integrity of the receptor subjected to 
prolonged exposure (2-3 days) to detergents can be significantly 
compromised if no additional stabilization is provided [24]. It was 
established that stabilization with the cholesterol derivative, CHS is 
essential to protect the correct fold of CB2. Depending on a duration 
of exposure of CB2 to detergents, 0.1 % (w/v) CHS can significantly 
increase the recovery of active receptor under these conditions while 
without CHS the receptor may lose activity rapidly within hours 
(Figure 4) [24]. Recovery of the functional activity was determined 
upon reconstitution of the receptor into POPC/POPS lipid bilayers, 
by measuring the rates of G protein activation by CB2 treated with the 
full agonist CP-55,940 as described [24]. These data correlate well 
with the reported ~0.11% CHS required for preservation of the 
ligand-binding capacity of another class A GPCR,  the adenosine A2a 
receptor [43]. While the mechanism of stabilization by CHS is not 
yet fully understood, it was speculated that the binding of this lipid-
like molecule to the receptor restricts its conformational flexibility 
and prevents irreversible denaturation [43]. Phospholipids, in 
particular negatively charged POPS and DOPS, are also very effective 
in stabilizing the functional fold of CB2 in detergents [24]. 
While CHS is quite effective for stabilization of CB2 in micelles, 
it cannot entirely protect the receptor from irreversible unfolding, 
especially for prolonged periods of time [24]. Thus, the addition of a 
high affinity ligand is required for further stabilization of CB2. For 
example, 10 M CP-55,940 in DDM/CHAPS/CHS micelles 
increased the yield of the functional protein by up to3-fold (Table 1). 
Low affinity ligands such as 2-AG were less efficient, while in the 
absence of ligands a significant fraction of active protein is lost [24]. 
All cannabinoid ligands including endogenous, plant-derived and 
synthetic cannabinoids are highly hydrophobic and partition readily 
into lipid membranes and detergent vesicles. We determined that for 
the highest recovery of active receptor, the ligand-receptor complex 
should be formed while CB2 still resides in E. coli membranes. This 
can be achieved by adding ligands (CP-55,940 or SR-144,528) 
during the induction of recombinant protein synthesis (Table 1) [24].  
In summary, select non-ionic and zwitterionic detergents, CHS 
and high affinity ligands have beneficial effects on protecting the 
functional structure of CB2, and their concerted action is necessary 
for isolation of fully functional receptor in a purified form. 
To further improve the long-term stability of the CB2, the 
purified receptor is reconstituted into lipid bilayers in a form of small 
spherical particles (proteoliposomes) [24, 34]. Proteoliposomes can 
be prepared by removal of detergents using detergent-absorbing resin 
or by rapid dilution of the lipid-protein-detergent mixture to below 
the CMC of the detergent (Figure 5). These particles typically have 
an average size of 120-130 nM, their size distribution is quite narrow, 
and the protein-to-lipid ratio is uniform within the proteoliposome 
fraction [34]. Typically, proteoliposomes are quite stable at 4 oC, so 
that the activity of the receptor in lipid bilayers can be maintained for 
at least two weeks at 4 oC. Functional activity was quantified by 
measuring the rates of G protein activation by the agonist-treated CB2 
and comparing them with that of the receptor in membrane 
preparations of E. coli [24]. The functional receptor in 
proteoliposomes was preserved for at least several months when 
stored at -80 oC [24]. 
The developed methods for expression, stable isotope labeling, 
purification, stabilization and liposome reconstitution open a path to 
meaningful NMR spectroscopic studies on the CB2 receptor. For 
example, a solution NMR can be applied to studies of the structure 
and interaction of CB2 with ligands in detergent micelles [21, 45]. 
However, the experimental setup can be complicated due to relatively 
short lifespan of the CB2 receptor in detergents, especially in micelles 
devoid of stabilizers (CHS and high affinity ligands). Rather, 
solubilization in isotropic bicelles [15, 46] or reconstitution into lipid 
bilayers in the form of proteoliposomes is preferred since a lipid 
environment better protects the functional structure of CB2. 
Proteoliposomes allow control over the composition of lipid matrix, 
provide long-term stability for the receptor and generate a native-like 
environment for studies of allosteric modulation of the functional 
state of GPCR [47]. For many solid state NMR applications 2-6 mg 
quantities of the liposome-reconstituted receptor may be required 
[34].  
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In addition, reconstitution of receptors into small lipoprotein 
particles (nanodiscs) is gaining increasing attention since such a 
system provides easy access to both extra- and intra-cellular surfaces 
of a GPCR and allows studies of interaction with G protein, -
arrestin and specific antibodies [48-53].  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Functional characterization of CB2 
 
Quantitative, reliable tests for the functional activity of the 
receptor are required for development of techniques of expression, 
stabilization, and purification of CB2. Measurement of binding of 
specific ligands to the recombinant receptor is typically used to assess 
the functionality of GPCR in cell membranes. Competitive 
displacement of the radiolabeled ligand [3H]-CP-55,940 with various 
cannabinoid agonists, antagonists and inverse agonists was performed 
on a bacterially expressed CB2 and revealed remarkable similarities in 
binding affinity and selectivity to that of CB2 in mammalian cell 
membranes [21]. The methodology for ligand binding on CB2-
containing membranes was published earlier [21], and typical 
saturation and competition ligand binding curves are presented in 
Figure 6. 
 
 
 
 
 
Additional complication comes from the fact that most 
cannabinoid ligands strongly partition into lipid bilayers or micelles 
which hampers determination of binding parameters. In particular, 
nonspecific retention of radioligand on proteoliposomes can reach as 
much as 80-90% of total binding [24]. To circumvent this problem, 
another functional test was developed that measures the rates of 
activation of G protein by an agonist-bound CB2 [22, 29]. The 
activated G  subunit dissociates from the receptor and catalyzes the 
exchange of GTP for GDP (Figure 7, A). By using radioactively 
labeled non-hydrolyzable analog of GTP, 35S--GTP, the rates of 
activation of G protein can be readily measured; this, in turn, provides 
valuable information about the functional state of the receptor [22, 
24]. The subunits of G protein can be expressed and purified as 
described [29]. This test utilizes mostly water-soluble components 
and is typically characterized by excellent signal-to-noise ratio [24]. 
The G protein activation test has been routinely used to assess the 
functionality of CB2 expressed as a fusion with MBP and affinity tags 
in E. coli membranes. The presence of N-terminal MBP and the C-
terminal Trx and small affinity tags such as His-tag do not affect the 
rates of activation of G proteins on an agonist-bound receptor [22, 
24]. The E. coli membranes are devoid of endogenous G protein, and 
Figure 4. Stabilization of CB2 by CHS. Stability of CB2 in detergent micelles 
at 4 oC was tested by measuring functional activity of CB2 reconstituted 
into proteoliposomes from detergent micelles with indicated content of 
CHS. The activity recovered from micelles supplemented with 0.1% CHS 
was set at 100%. The receptor was incubated in buffers with indicated 
content of CHS overnight at 4 oC, and reconstituted into POPC/POPS/CHS 
lipid matrix in a form of proteoliposomes. The functional activity was 
determined by measuring the rates of G protein activation by the 
liposome-reconstituted receptor in the presence of a saturating 
concentration of agonist CP-55,940. Representative data from a typical 
experiment (out of a total of 3) are presented; each point is an average of 
two measurements. (Data reproduced from [24]). 
 
Figure 5. Preparation of proteoliposomes containing purified CB2. 
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thus contribute very little to the signal measured by the amount of Gα 
-35S--GTP. The activation of G protein on E. coli membranes 
expressing CB2 upon titration with the high affinity agonist CP-
55,940 occurs in a concentration-dependent manner with the 
estimated EC50 = 1.3 nM (T = 30 oC) (Figure 7, B). The EC50 for 
CP-55,940 measured on CB2 expressed in CHO cell line was very 
similar (EC50 = 1.37 nM, T= 30 oC) to the values obtained for the 
bacterially expressed receptor, confirming full functionality of the 
MBP-CB2 fusion in E. coli membranes [24]. 
 
 
 
 
 
 
 
 
 
 
 
While the CB2 in membrane preparations exhibits robust 
activation of G protein in response to agonist binding, this assay 
cannot be performed on a receptor solubilized in detergent micelles 
since detergents disrupt the interaction of G protein with CB2 [24]. 
Therefore, the purified CB2 is reconstituted into small 
proteoliposomes, and detergents are removed by dialysis or by 
treatment with detergent-absorbing resin. The purified receptor is 
capable of activating G protein upon binding of the agonist CP-
55,940 [24]. The assay is very sensitive and as little as 2-3 ng of the 
receptor can be used per sample. The rates of activation are, 
obviously, affected by the orientation of the reconstituted receptor in 
proteoliposomes. In POPC/POPS bilayers the receptor is 
reconstituted in a random orientation so that only ~50% of CB2 
molecules are available for interaction with G protein [24]. Unlike 
proteoliposomes, in a typical E. coli membrane preparation the C-
terminal part of CB2 appears to be fully accessible for interaction with 
the large MBP- TEV protease fusion providing indirect evidence for 
its accessibility for G protein binding [24]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Saturation (A) and competition (B) binding assay with [3H]-CP-
55,940 on E. coli membranes expressing CB2-130. Twenty micrograms of 
membrane preparations containing CB2 were used per reaction, and the 
assay was performed as described in [21]. Each point represents an 
average of duplicate measurements (adapted from [21]). 
 
Figure 7. Functional characterization of CB2 by G protein-activation assay. 
(A), a complex of Gα subunit of G protein with the non-hydrolyzable 
analog of GTP is generated upon activation of G protein on an agonist-
bound receptor. The rates of accumulation of the 35S--GTP-Gαi1 complex 
are proportional to the rate of activation of G protein on a receptor; (B), 
CP-55,940 dose-dependent activation of G protein by CB2-130 in E. coli 
membranes. Concentration of components:  3 nM CB2, 100 nM Gαi1, 200 
nM G12 in the presence of 35S--GTP and variable concentrations of CP-
55,940 solubilized in 10 mM MOPS pH 7.5 supplemented with 0.1% BSA in 
50 L reaction volume as described in [21, 24]. Reactions were started by 
addition of the radiolabeled analog of GTP, proceeded for 20 minutes at 
30oC, and were terminated by addition of 2 mL of the ice-cold stop 
solution (Tris/MgCl2/NaCl). Reactions were then filtered through 0.45  
nitrocellulose filters and retained radioisotope counted upon addition of 
scintillation liquid (adapted from [24]). 
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The rates of G protein activation are affected by the composition 
of lipid matrix of proteoliposomes. The presence of ~50% of 
phospholipids with negatively charged headgroup (i.e. POPS) in lipid 
bilayers results in the highest activation rate, presumably through 
more efficient stabilization of the receptor in active conformation 
[34]. The effect of the negative charge of phospholipids on activation 
rate of G protein appears to be receptor-specific since in the case of 
another class A GPCR, recombinant neurotensin receptor, ~100% 
content of negatively charged POPG resulted in the highest rates of 
activation of G protein [54]. 
 
Concluding remarks 
 
We reviewed the methodology for expression, purification, 
stabilization and functional characterization of human cannabinoid 
receptor CB2. Expression of CB2 in E. coli as an N-terminal fusion 
with MBP yields fully functional receptor localized to the cytoplasmic 
bacterial membranes. Small affinity tags at the opposing ends of CB2 
allow efficient purification with high recovery. Due to poor stability 
of the receptor in detergent micelles special care should be taken to 
preserve the functional fold of CB2. This is achieved by adding high 
affinity cannabinoid ligands and the cholesterol derivative CHS to 
detergent micelles during chromatographic purification of CB2. 
Furthermore, the addition of the cannabinoid ligand to the growth 
medium in the course of induction of CB2 synthesis significantly 
increases the yield of the functional receptor. 
Long-term stability of CB2 is achieved by reconstituting the 
protein into lipid bilayers in a form of small spherical particles 
(proteoliposomes). The proteoliposomes are amenable to 
characterization by ligand binding and G protein activation assays. 
The structure and function of the receptor imbedded in lipid bilayers 
can then be studied by a variety of biophysical techniques including 
fluorescence-, CD, EPR, and NMR spectroscopy. 
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